Biologic & Biosimilar Access

NASPGHAN Grassroots Calls to Action

Take Action: Ask Congressional Lawmakers to support the Safe Step Act

NASPGHAN Communications

GI Society Letter to Blue Cross Blue Shield Regarding Draft Policy on Infliximab and Biosimilars
November 5, 2024

NASPGHAN Comments to FDA on Draft Biosimiliar and Interchangeable Biosimilar Labeling Guidance
November 17, 2023

NASPGHAN Letter to Senate Health, Education, Labor and Pensions Committee Chairman Sanders on Biologic Interchangeability
September 6, 2023

NASPGHAN, ASGE, AGA and ACG Letter to Health, Education, Labor and Pensions Committee Chairman Sanders and Ranking Member Cassidy Regarding Payer Interference in Biologic Prescribing
April 10, 2023

NASPGHAN, ASGE, AGA and ACG Letter to Ways and Means Committee Leadership Regarding Payer Interference in Biologic Prescribing
April 10, 2023

NASPGHAN, AAP, AGA, ACG, ASGE Letter to Aetna
August 12, 2021

NASPGHAN, AGA, ACG, ASGE Letter to Cigna
June 9, 2021

NASPGHAN Endorsement of the Safe Step Act (H.R. 2163)
April 29, 2021

NASPGHAN Endorsement of the Safe Step Act (S. 464)
April 29, 2021

NASPGHAN, AGA, ACG, ASGE Joint Communication UnitedHealthcare Makes Changes to Remicade Coverage Policy at Request of GI Societies
February 2021

NASPGHAN, AGA, ACG, ASGE Letter to UnitedHealthcare
January 28, 2021

NASPGHAN, AGA, ACG, ASGE Letter to UnitedHealthcare
January 19, 2021

Payer Policies

Cigna Medication Coverage Changes: July-December 2021

UnitedHealthcare Commercial Medical Benefit Drug Policy, April 1, 2021

Resources 

NASPGHAN Payer Interference with Biologic Prescribing Reporting Portal

Safe Step Act (H.R. 2163)

Safe Step Act (S. 464)

NASPGHAN Sample Advocacy Letters for Children with Crohn’s and Ulcerative Colitis 

Crohn’s & Colitis Foundation Customizable Appeals Letters